Contact
Pharma Data | Q&As & Interviews

Regulation & Policy Interview with Damion Nero, Head of Data Science at Takeda

Edited by Tia Byer | 17 February 2023
Damion Nero, Head of Data Science at Takeda, discusses the regulatory challenges and opportunities of Real-World Data.
https://www.youtube.com/watch?v=syoLErXSGVE

Get your weekly dose of industry news and announcements here, and keep up to date with the latest ‘Industry Spotlight’ posts. For other PharmaTec content, please visit the PharmaTec Content Portal.

Want to find out more about the innovations happening in pharma data? Join Oxford Global’s annual Pharma Data & Digital Medicine event today. This 2-day conference brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and exciting industry outlooks.

Speaker Biographies

Damion Nero, is currently Head of Data Science at Takeda. He has 14 years of experience in Real World Evidence research and Health Economics and Outcomes Research, with background in using statistics and machine learning methods to analyse large scale datasets, including administrative claims Electronic Medical Records.

Nero also has extensive experience working with survey data and patient reported outcomes, as well as a familiarity in using statistical data packages and Python code for advanced modelling techniques.

He has worked with many leading pharmaceutical, medical device and biotech companies, as well as state and government agencies. Nero has also worked on all aspects of project development, from proposal drafting to protocol/analytic plan development and production of deliverables.

Related Resources

Funding Opportunity Announced for Generating Real-World Evidence in Regulatory Decision-Making

The U.S. Food and Drug Administration (FDA) is encouraging pharmaceutical developers to submit real-world evidence in support of regulatory applications.
Read More

The Evolution of Pharma Data Practices

Pharma data practices have evolved with the times. Today, approaches such as AI and machine learning afford the opportunity to enhance drug development and safety, culminating in AI-driven insights that promise better patient outcomes.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
20/03/24
The Design of Novel Drugs with Generative AI